Text

The New Drug Reimbursement Game

---

The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.

---

Availability

No copy data

Detail Information

Series Title

-

Call Number

-

Publisher

Cham : Adis Cham., 2014

Collation

XVI, 248

Language

English

ISBN/ISSN

978-3-319-08903-4

Classification

NONE

Content Type

text

Media Type

computer

Carrier Type

-

Edition

-

Subject(s)

Pharmacology, Pharmaceutics

Specific Detail Info

-

Statement of Responsibility

Brita A.K. Pekarsky

Other Information

Cataloger

Jemadi

Source

https://link.springer.com/content/pdf/10.1007/978-3-319-08903-4.pdf?pdf=button

Validator

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment